middle.news
How Patrys’ Reliis Acquisition Could Accelerate CNS Therapeutics Progress
8:30am on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
How Patrys’ Reliis Acquisition Could Accelerate CNS Therapeutics Progress
8:30am on Friday 30th of January, 2026 AEDT
Key Points
Acquisition of Reliis Pty Ltd adds CNS therapeutic asset RLS-2201
RLS-2201 targets delirium in ICU, aged-care, and palliative settings
Near-term clinical and regulatory milestones expected from new asset
Continued development of deoxymab platform for inflammatory diseases
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Patrys (ASX:PAB)
OPEN ARTICLE